MIAMI, Feb. 7, 2008 (PRIME NEWSWIRE) -- Galea Life Sciences, Inc. (Pink Sheets:GLSN) announces that its wholly owned subsidiary, BioSource Therapeutics, Inc. (BST), has submitted its clinical policy abstract to AIDS 2008 -- the 17th International AIDS Conference -- being held August 3-8, 2008 in Mexico City. BST is the maker of Nutraplete Therapeutic Drink Mix, the first dietary supplement product designed specifically for people living with HIV/AIDS.
Titled "Nutritional Intervention and the Management of Oxidative Stress in the Long Term Management of HIV Infection in the Era of HAART," this abstract advocates for the evidence-based utilization of Nutraplete as a standard component for the treatment of involuntary HIV/AIDS-associated muscle loss. More importantly, it was designed to correct micronutrient deficiencies found in patients diagnosed with HIV infection and serve as a requisite adjunct to Highly Active Antiretroviral Therapy (HAART), the prescribed course of treatment for people living with HIV/AIDS. Nutraplete works in conjunction with HAART by helping to ease side effects such as diarrhea and nausea, and allowing HIV/AIDS patients to remain adherent to often difficult-to-take drug regimens. Nutraplete also reduces pro-oxidative stress, supports the immune system, helps to prevent muscle loss and rebuilds essential muscle by providing important micronutrients, protein and enzymes. If accepted, the Company will present this abstract at the Mexico City conference in August.
According to Dr. Robert Keller, MD, MS, FACP, AAHIVS, Clinical Advisor and head of BioSource Therapeutics, Inc.'s Scientific Advisory Board, "It's illogical to utilize HAART therapy to suppress HIV without first correcting the nutritional and antioxidant deficiencies caused by the virus. Nutraplete is the first and most complete nutritional supplement designed specifically for HIV/AIDS that addresses all of the inherent nutritional and antioxidant problems associated with this disease."
"World awareness is focusing on HIV/AIDS nutrition-related implications and consequences for individuals, families, and communities," said Dr. Terence M. Dolak, Ph.D., BST's Chief Scientific Advisor. Nutraplete, as a key nutritional support element of a therapeutic regimen, can help bolster nutritional values which increases medication efficacy and adherence, and can help slow the progression of disease in infected individuals."
About the 17th International AIDS Conference
The International AIDS Society (IAS) is convening AIDS 2008: the 17th International AIDS Conference in Mexico City, August 3-8. 2008. With over 25,000 attendees expected, this promises to be the largest gathering of professionals and community stakeholders in the history of the HIV/AIDS crisis. The Conference emphasizes scientific excellence and inquiry, encourages individual and collective action and dialogue, and fosters social accountability. Universal Action Now is the conference theme, emphasizing the need for continued urgency in the worldwide response to the HIV/AIDS pandemic at global, national, regional and local levels. Webcasts and related resources for major Conference sessions will be available from: www.kaisernetwork.org
For more information: www.aids2008.org
About Nutraplete
Nutraplete is the first therapeutic dietary supplement designed specifically for people living with HIV/AIDS. It is a multi-nutritional supplement, designed to address AIDS Wasting Syndrome. It works in conjunction with antiviral therapies and assists patients in the adherence and tolerance of treatments. Nutraplete is a "functional food" that encourages the restoration of lean body mass, can inhibit pro-oxidative stress, and improves immune function. Nutraplete is available by prescription, and has started the application process for inclusion with Medicaid and AIDS Drugs Assistance Program (ADAP) formularies. Nutraplete is distributed nationally by Allion Healthcare, Inc. (Nasdaq:ALLI) under its MOMS Pharmacy trade name. www.momspharmacy.com
For more information: www.nutraplete.com
About Galea Life Sciences, Inc.
Galea Life Sciences, Inc. (Pink Sheets:GLSN) is currently a non-reporting over-the-counter, publicly traded company. GLSN identifies and acquires new and innovative nutraceutical product and dietary supplement companies with outstanding growth potential. GLSN's focus is in the emerging scientific field of advanced nutritional supplements designed to support traditional medical treatments and therapies. BioSource Therapeutics, Inc. (BST), a GLSN subsidiary, is an entrepreneurial life sciences company. BST specializes in the formulation, manufacturing, marketing and distribution of innovative dietary supplements that benefit people undergoing medical treatments and therapies.
The Galea Life Sciences logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=4489
Certain statements in this release constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words `forecast,' `project,' `intend,' `expect' `should,' `would,' and similar expressions and all statements, which are not historical facts, are intended to identify forward-looking statements. These forward-looking statements involve and are subject to known and unknown risks, uncertainties and other factors which could cause the Company's actual results, performance (finance or operating) or achievements to differ from future results, performance (financing and operating) or achievements expressed or implied by such forward-looking statements.
Statements herein express management's beliefs and expectations regarding future performance and are forward-looking and involve risks and uncertainties, including, but not limited to, the ability to negotiate outstanding prior debts of acquired companies; properly identify acquisition partners; adequately perform due diligence; manage and integrate acquired businesses; react to quarterly fluctuations in results; raise working capital and secure other financing; respond to competition and rapidly changing technology; deal with market and stock price fluctuations; and other risks.